|Videos|July 23, 2021
First Vyluma product tackles pediatric myopia
Advertisement
Dive deep into Vyluma’s investigational atropine therapy. Navneet Puri, PhD, the company’s founder, chairman, and CEO, explains details of the clinical trials.
Newsletter
Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
Dry eye and macular degeneration: A convergence of aging, inflammation, and telomere biology
2
Dry eye an area of prime interest to ODs and MDs in 2025
3
Detecting glaucoma progression based on multiple retinal layers' thickness
4
Refractive surgery for myopia vs presbyopia: Tailoring the approach for the individual
5